Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.

Autor: Kirienko M; Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Gelardi F; Vita-Salute San Raffaele University, Via Olgettina 58, Milan, 20132, Italy., Fiz F; Department of Nuclear Medicine, E.O. 'Ospedali Galliera', Genoa, Italy.; Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany., Bauckneht M; Department of Health Science (DISSAL), University of Genoa, Genoa, Italy.; Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Ninatti G; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. g.ninatti@campus.unimib.it.; Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, 20132, Italy. g.ninatti@campus.unimib.it., Pini C; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, 20132, Italy., Briganti A; Vita-Salute San Raffaele University, Via Olgettina 58, Milan, 20132, Italy.; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy., Falconi M; Vita-Salute San Raffaele University, Via Olgettina 58, Milan, 20132, Italy.; Pancreatic and Transplant Surgery Unit, San Raffaele Hospital, Vita-Salute University, Milan, Italy., Oyen WJG; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Nuclear Medicine, Humanitas Clinical and Research Center, Milan, Italy., A van der Graaf WT; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Sollini M; Vita-Salute San Raffaele University, Via Olgettina 58, Milan, 20132, Italy.; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Sep 11. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1007/s00259-024-06882-9
Abstrakt: Purpose: For several years, oncological positron emission tomography (PET) has developed beyond 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG). This umbrella review of meta-analyses aims to provide up-to-date, comprehensive, high-level evidence to support appropriate referral for a specific radiopharmaceutical PET/computed tomography (CT) or PET/magnetic resonance (MR) in the diagnosis and staging of solid cancers other than brain malignancies.
Methods: We performed a systematic literature search on the PubMed/MEDLINE and EMBASE databases for meta-analyses assessing the accuracy of PET/CT and/or PET/MRI with [ 18 F]FDG, somatostatin- receptor-targeting 68 Ga-DOTA-peptides, 18 F-labelled dihydroxyphenylalanine ([ 18 F]DOPA), prostate-specific membrane antigen (PSMA)-targeted radioligands, and fibroblast activation protein inhibitors (FAPI) in the diagnosis/disease characterisation and staging of solid cancers other than brain tumours.
Results: The literature search yielded 449 scientific articles. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 173 meta-analyses to assess the strength of evidence. One article was selected from references. Sixty-four meta-analyses were finally considered. The current evidence corroborates the role of [ 18 F]FDG as the main player in molecular imaging; PSMA tracers are useful in staging and re-staging prostate cancer; somatostatin-targeting peptides (e.g. [ 68 Ga]Ga- DOTA-TOC and -TATE) or [ 18 F]DOPA are valuable in neuroendocrine tumours (NETs). FAPI has emerged in gastric cancer assessment. According to search and selection criteria, no satisfactory meta-analysis was selected for the diagnosis/detection of oesophageal cancer, the diagnosis/detection and N staging of small cell lung cancer and hepatic cell carcinoma, the diagnosis/detection and M staging of melanoma and Merkel cell carcinoma, cervical, vulvar and penis cancers, the N and M staging of lung and gastroenteropancreatic NET, testicular cancer, and chondrosarcoma, and the M staging of differentiated thyroid, bladder and anal cancers.
Conclusion: The comprehensive high-level evidence synthesised in the present umbrella review serves as a guiding compass for clinicians and imagers, aiding them in navigating the increasingly intricate seascape of PET examinations.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: